Get The Daily Rip

Stocktwits Top 25 – Week 52 ๐Ÿ“‰

Welcome to the Stocktwits Top 25 Newsletter for Week 52 of 2022!

The Stocktwits Top 25 reports the 25 best-performing stocks in the S&P 500, Nasdaq 100, and Russell 2000 year to date (YTD) and tracks their performances over time.ย 

Here are the Stocktwits Top 25 Lists for Week 52:


Standard and Poor's 500

ST Top 25 S&P 500

The S&P 500 Top 25 list (-0.72%) underperformed the S&P 500 index (-0.14%).ย 

The year-to-date leaders in this list remained in the energy, health care, and consumer staples sector as they did for most of the year. Notice that technology, communication services, and consumer discretionary are nowhere to be found on the list, given they led to the downside all year.

And next week, we begin again with a brand new scorecard.

Check out how the momentum meter has performed vs. the S&P 500 index this year:


NASDAQ 100

The Large-Cap Nasdaq 100

The Nasdaq 100 Top 25 list (-0.47%) underperformed the Nasdaq 100 index (-0.42%).

Despite being the tech-heavy Nasdaq 100, the leaderboard for the year ended with a lack of technology stocks. Instead, energy, health care, and defensive areas like consumer staples topped the list.

Overall performance for the index was so bad that some stocks cracked into the top 25 by simply falling a lot less than others.

Let’s see what next year’s performance brings.


RUSSELL 2000

The Growth-Centric Russell 2000

The Russell 2000 Top 25 list (+2.34%) outperformed the Russell 2000 index (-0.02%).

As expected, the Russell 2000’s list had the largest percentage gainers this year. Like the other lists, many of its constituents came from the energy and health care sectors. However, unlike the other lists, there was more diversity of sectors and industries here.

And now we wait to see what happens in 2023.


๐Ÿถ๐Ÿถ๐Ÿถ

ST Top 25 TOP DAWG OF THE WEEK ๐Ÿถ

The Top 25 lists’ Top Dawg was Ardelyx,ย which rallied 18.26%. ๐Ÿ“ˆ

The small-cap biotech company rose sharply on news that the FDA granted its appeal for its new Xphozah drug application. The stock has been trending higher since June with many other biotech stocks but pushed to new year-to-date highs on the news.ย 

$ARDX is up 141.53% YTD.

See Yโ€™all Next Week ๐Ÿค™